Faeth Therapeutics Posts $16M Q2 Loss, $186M Cash; PIKTOR Data Readouts on Track
FTH has more than doubled off its 52-week low of $7.1 on elevated volume (2.1× avg).
Summary
Faeth Therapeutics reported Q2 2026 results with a net loss of $16.0 million, or $2.84 per share, on operating expenses of $18.4 million. Cash and equivalents stood at $186.4 million as of June 30, 2026, providing runway to advance its lead asset PIKTOR. The company confirmed topline data from the Phase 2 PIK-201 trial in endometrial cancer remains on track for year-end 2026, and the first patient was dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer. This follows the recent merger with Sensei Biotherapeutics and a $200 million PIPE financing, which transformed the company's balance sheet and pipeline. The cash position and upcoming catalysts make this a pivotal period for the newly named entity.
At the time of this announcement, FTH was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $704.8M. The 52-week trading range was $7.10 to $37.90. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.